Healthcare provider profile · identity verified

Hemant T Thawani, MD

Endocrinology · GRAND BLANC, MI · NPI 1770545964

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	1728	498
Trulicity	Dulaglutide	547	130
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	546	194
Metformin Hcl Er	Metformin Hcl	321	114
Jardiance	Empagliflozin	277	97
Novolog Flexpen	Insulin Aspart	273	100
Ozempic	Semaglutide	237	69
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	234	125
Glipizide	Glipizide	233	94
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	233	101
Humalog Kwikpen U-100	Insulin Lispro	218	98
Rosuvastatin Calcium	Rosuvastatin Calcium	209	77
Metformin Hcl	Metformin Hcl	205	73
Methimazole	Methimazole	204	67
Atorvastatin Calcium	Atorvastatin Calcium	183	62
Ezetimibe	Ezetimibe	170	54
Mounjaro	Tirzepatide	169	39
Losartan Potassium	Losartan Potassium	159	62
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	140	49
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	110	48
Januvia	Sitagliptin Phosphate	101	30
Metoprolol Succinate	Metoprolol Succinate	87	30
Fenofibrate	Fenofibrate	85	29
Hydrochlorothiazide	Hydrochlorothiazide	83	29
Duloxetine Hcl	Duloxetine Hcl	78	26
Lisinopril	Lisinopril	78	28
Calcitriol	Calcitriol	73	22
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	73	30
Cinacalcet Hcl	Cinacalcet Hcl	71	24
Alendronate Sodium	Alendronate Sodium	63	24
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	63	20
Rybelsus	Semaglutide	62	17
Droplet Pen Needle	Pen Needle, Diabetic	58	35
Spironolactone	Spironolactone	58	21
Synthroid	Levothyroxine Sodium	57	18
Amlodipine Besylate	Amlodipine Besylate	56	22
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	49	19
Comfort Ez Pen Needle	Pen Needle, Diabetic	48	22
Testosterone Cypionate	Testosterone Cypionate	46	14
Gabapentin	Gabapentin	44	18
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	43	15
Hydrocortisone	Hydrocortisone	41	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	41	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	41	12
Humalog	Insulin Lispro	38	12
Levemir Flexpen	Insulin Detemir	36	23
Novolog	Insulin Aspart	36	13
Tresiba Flextouch U-100	Insulin Degludec	36	15
Humulin R U-500 Kwikpen	Insulin Regular, Human	34	suppressed
Tymlos	Abaloparatide	34	suppressed
Humulin R	Insulin Regular, Human	30	suppressed
Trazodone Hcl	Trazodone Hcl	30	suppressed
Simvastatin	Simvastatin	29	suppressed
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	29	suppressed
Carvedilol	Carvedilol	28	suppressed
Potassium Chloride	Potassium Chloride	27	16
Amiloride Hcl	Amiloride Hcl	26	suppressed
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	26	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	25	12
Invokana	Canagliflozin	25	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Pravastatin Sodium	Pravastatin Sodium	24	suppressed
Creon	Lipase/Protease/Amylase	23	suppressed
Prednisone	Prednisone	23	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	22	12
Icosapent Ethyl	Icosapent Ethyl	22	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	22	16
Cabergoline	Cabergoline	21	suppressed
Atenolol	Atenolol	20	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	20	suppressed
Farxiga	Dapagliflozin Propanediol	19	suppressed
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	19	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Omeprazole	Omeprazole	19	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Insulin Aspart Flexpen	Insulin Aspart	17	12
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Glimepiride	Glimepiride	16	suppressed
Omnipod 5 Dexg7g6 Pods (Gen 5)	Insulin Pump Cart,auto,bt,g6/7	16	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	15	suppressed
Novolin R Flexpen	Insulin Regular, Human	15	suppressed
Np Thyroid	Thyroid,pork	15	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Finasteride	Finasteride	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Pen Needles	Pen Needle, Diabetic	14	suppressed
Admelog Solostar	Insulin Lispro	13	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	13	suppressed
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	13	suppressed
Humulin R U-500	Insulin Regular, Human	13	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Repatha Sureclick	Evolocumab	13	suppressed
Acarbose	Acarbose	12	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Easy Touch Pen Needle	Pen Needle, Diabetic	12	suppressed
Glucagon Emergency Kit	Glucagon	12	11
Pen Needle	Pen Needle, Diabetic	12	suppressed
Teriparatide	Teriparatide	12	suppressed
Ulticare Pen Needle	Pen Needle, Diabetic	12	suppressed
Allopurinol	Allopurinol	11	suppressed
Novolin R	Insulin Regular, Human	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error